1-tert-butoxycarbonyl-5-hydroxypiperidine-2-carboxylic acid | 131950-00-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-tert-butoxycarbonyl-5-hydroxypiperidine-2-carboxylic acid
• 英文别名: 1-tert-Butoxycarbonyl-5-hydroxy-piperidine-2-carboxylic acid；5-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-2-carboxylic acid
• CAS: 131950-00-0
• 化学式: C₁₁H₁₉NO₅
• 分子量: 245.276
• InChiKey: DKOIPAZERNXIHU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  87.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  5-羟基-2-吡啶羧酸 在 palladium 10% on activated carbon 、 氢气 、 溶剂黄146 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 25.0~50.0 ℃ 、344.75 kPa 条件下， 反应 30.0h， 生成 1-tert-butoxycarbonyl-5-hydroxypiperidine-2-carboxylic acid
  参考文献：
  名称：

  RAD51 Inhibitors

  摘要：

  这个应用程序是针对由以下结构式代表的RAD51抑制剂，以及它们的使用方法，例如用于治疗癌症、自身免疫疾病、免疫缺陷或神经退行性疾病。

  公开号：

  US20190077799A1

文献信息

• METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER
  申请人：Cyteir Therapeutics, Inc.

  公开号：US20200397760A1

  公开（公告）日：2020-12-24

  This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat pancreatic cancer.

  这个应用程序是针对由以下结构式代表的RAD51抑制剂，以及它们的使用方法，例如用于治疗胰腺癌。
• [EN] HYDROXYMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DES OREXINES DE TYPE PIPÉRIDINE HYDROXYMÉTHYLIQUE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016089722A1

  公开（公告）日：2016-06-09

  The present invention is directed to hydroxymethyl piperidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及羟甲基哌啶类化合物，其为促进睡眠的受体拮抗剂。本发明还涉及所述化合物在潜在的治疗或预防神经系统和精神疾病中的用途，这些疾病涉及促进睡眠的受体。本发明还涉及含有这些化合物的组合物。本发明还涉及利用这些组合物在潜在的预防或治疗涉及促进睡眠的受体的疾病中的用途。
• Method for Producing cis-5-hydroxy-2-piperidinecarboxylic Acid Derivative, and Method for Purifying cis-5-hydroxy-2-piperidinecarboxylic Acid
  申请人：API CORPORATION

  公开号：US20150239906A1

  公开（公告）日：2015-08-27

  The present invention aims to provide a method for purifying cis-5-hydroxy-2-piperidinecarboxylic acid with high purity, and a method for producing its derivative. The present invention provides a method for producing a cis-5-hydroxy-2-piperidinecarboxylic acid derivative, which method comprises a step of converting cis-5-hydroxy-2-piperidinecarboxylic acid into a compound(s) of Formula (1) and/or Formula (2) (wherein R 1 represents a protective group for an amino group, and R2 represents a C 1 -C 6 alkyl group), and a method for purifying cis-5-hydroxy-2-piperidinecarboxylic acid.

  本发明旨在提供一种高纯度纯化顺式-5-羟基-2-哌啶羧酸的方法，以及其衍生物的生产方法。本发明提供了一种生产顺式-5-羟基-2-哌啶羧酸衍生物的方法，该方法包括将顺式-5-羟基-2-哌啶羧酸转化为式（1）和/或式（2）化合物的步骤（其中R1代表氨基的保护基，R2代表C1-C6烷基），以及一种纯化顺式-5-羟基-2-哌啶羧酸的方法。
• RAD51 inhibitors
  申请人：Cyteir Therapeutics, Inc.

  公开号：US10336746B1

  公开（公告）日：2019-07-02

  This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.

  本申请涉及以下列结构式为代表的 RAD51 抑制剂、 及其使用方法，如治疗癌症、自身免疫性疾病、免疫缺陷或神经退行性疾病。
• METHOD FOR PRODUCING cis-5-HYDROXY-2-PIPERIDINECARBOXYLIC ACID DERIVATIVE, AND METHOD FOR PURIFYING cis-5-HYDROXY-2-PIPERIDINECARBOXYLIC ACID
  申请人：API Corporation

  公开号：EP2889288B1

  公开（公告）日：2018-07-25